Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller Sells 8,900 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller sold 8,900 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $497.30 on Thursday. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a 50 day moving average price of $569.42 and a 200 day moving average price of $531.60. The firm has a market capitalization of $177.13 billion, a price-to-earnings ratio of 77.58, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43.

Hedge Funds Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $2,401,493,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Intuitive Surgical in the third quarter worth $558,807,000. Proficio Capital Partners LLC increased its position in shares of Intuitive Surgical by 89,098.8% in the fourth quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock worth $495,845,000 after acquiring an additional 948,902 shares in the last quarter. FMR LLC increased its position in shares of Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after acquiring an additional 838,793 shares in the last quarter. Finally, Capital Research Global Investors increased its position in shares of Intuitive Surgical by 25.5% in the fourth quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock worth $1,764,904,000 after acquiring an additional 687,906 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on ISRG shares. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Stifel Nicolaus upped their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Evercore ISI upped their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Citigroup upped their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Finally, Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $522.00 to $650.00 in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.